<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: The treatment with antitumor <z:mp ids='MP_0001651'>necrosis</z:mp> factor agents has often been associated with the induction of autoantibodies (<z:hpo ids='HP_0003493'>antinuclear antibodies</z:hpo>, anti-<z:chebi fb="0" ids="4705">double stranded DNA</z:chebi> antibodies and <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo>) </plain></SENT>
<SENT sid="1" pm="."><plain>The clinical significance of these antibodies remains unclear, but they may predispose to <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> with thromboembolic complications </plain></SENT>
<SENT sid="2" pm="."><plain>The association of etanercept with <z:hpo ids='HP_0001907'>thromboembolic events</z:hpo> has not been reported previously in the literature </plain></SENT>
<SENT sid="3" pm="."><plain>CASE PRESENTATION: We describe the cases of three patients with <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo>, psoriatic <z:hpo ids='HP_0001369'>arthritis</z:hpo> and seronegative inflammatory <z:hpo ids='HP_0001369'>arthritis</z:hpo> who were treated with etanercept </plain></SENT>
<SENT sid="4" pm="."><plain>They developed <z:hpo ids='HP_0002625'>deep vein thrombosis</z:hpo> and/or <z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo> one to three years after the initiation of etanercept therapy </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> three patients had a <z:hpo ids='HP_0003645'>prolonged activated partial thromboplastin time</z:hpo> with a positive <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> that persisted even after 12 weeks </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: Although the clinical significance of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> during treatment with antitumor <z:mp ids='MP_0001651'>necrosis</z:mp> factor agents remains unclear, they may predispose patients to develop <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> when associated with <z:hpo ids='HP_0003645'>prolonged activated partial thromboplastin time</z:hpo>, <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> positivity, or the presence of anti-beta2 <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I </plain></SENT>
<SENT sid="7" pm="."><plain>Clinicians must keep this in mind during therapy with antitumor <z:mp ids='MP_0001651'>necrosis</z:mp> factor agents in order to prevent, detect and treat potential consequences such as <z:hpo ids='HP_0002625'>deep vein thrombosis</z:hpo> and <z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo> </plain></SENT>
</text></document>